OCA 983
OCA 983 is an orally active tetrahydrofuranyl 1β-methylcarbapenem antibiotic. OCA 983 exhibits potent inhibitory activity against class A and class C β-lactamases. OCA 983 possesses a broad antibacterial spectrum, and can be used in the research of infectious diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 161856-02-6
- Formule: C20H31N3O6S
- Masse moléculaire:441.54
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Antibiotic
MoreVoir tous les produits spécifiques à Isoform Beta-lactamase
More
Activité biologique
Description
Chemical Information
-
CAS No. 161856-02-6
-
Masse moléculaire 441.54
-
Formule C20H31N3O6S
-
SMILES
OC(C1=C(S[C@H]2[C@H](OCC2)CNC([C@@H](N)C(C)C)=O)[C@H](C)[C@@]([C@@]3([H])[C@H](O)C)([H])N1C3=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
[1]. Jiraskova N. THF carbapenems. Wyeth Ayerst. Curr Opin Investig Drugs. 2001 Aug;2(8):1035-8. [Content Brief]
[2]. Bitha P, et al. Convergent syntheses of oral THF 1beta-methylcarbapenems. J Antibiot (Tokyo). 1999 Jul;52(7):643-8. [Content Brief]
[3]. Bronson JJ, et al. Quinolone, everninomycin, glycylcycline, carbapenem, lipopeptide and cephem antibacterials in clinical development. Curr Med Chem. 2001 Dec;8(14):1775-93. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
OCA 983 Related Classifications
HY-105914 Related Classifications
Powered by Bioz